BiotechTube
Home/Pipeline/Self-amplifying mRNA Vaccines

Self-amplifying mRNA Vaccines

Not Specified

Pre-clinicalActive

Key Facts

Indication
Not Specified
Phase
Pre-clinical
Status
Active
Company
ExcepGen

About ExcepGen

ExcepGen is a private, pre-clinical stage biotech developing a novel platform, RNAx, to create more tolerable RNA vaccines and therapeutics. The platform addresses a key limitation of current nucleic acid medicines—excessive innate immune activation—by encoding a regulatory protein within the mRNA itself. Led by a team with expertise in biochemistry and synthetic biology, the company is advancing initiatives in self-amplifying, trans-amplifying, and conventional mRNA vaccines, aiming to unlock the full potential of RNA-based medicine with a safety profile closer to the standard of care.

View full company profile

Therapeutic Areas

Infectious Diseases

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved